Panitumumab
Egfr (Epidermal Growth Factor Receptor) Inhibitors
Sold as VECTIBIX
- Drug class
- Egfr (Epidermal Growth Factor Receptor) Inhibitors
- Availability
- See label
- Routes
- Intravenous
- Markets covered
- 3
- Products on record
- 8
Overview
Panitumumab is an active pharmaceutical ingredient in the Egfr (Epidermal Growth Factor Receptor) Inhibitors group (L01FE). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 4 | August 22, 2025 |
| CA Canada | Health Canada | 3 | March 22, 2025 |
| EU European Union | EMA | 1 | May 7, 2025 |
GBUnited Kingdom· MHRA
4 products
Uses
Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC): • in first-line in combination with FOLFOX or FOLFIRI. • in second-line in combination with FOLFIRI for patients who have received first- line fluoropyrimidine-based chemotherapy (excluding irinotecan).
• as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens.
How to take
CACanada· Health Canada
3 products
Uses
VECTIBIX (panitumumab for injection) is indicated: for the treatment of previously untreated patients with non-mutated (wild-type) RAS metastatic colorectal carcinoma (mCRC) in combination with FOLFOX (infusional 5- fluorouracil, leucovorin, and oxaliplatin).
as monotherapy for the treatment of patients with non-mutated (wild-type) RAS mCRC after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. 1 Pediatrics The safety and effectiveness of VECTIBIX in pediatric patients (< 18 years of age) have not been established.
2 Geriatrics Of the 737 patients with wild-type KRAS mCRC who received VECTIBIX monotherapy in Studies 20020408 and 20080763 (see 14 CLINICAL TRIALS), 36% were 65 years of age and over while 8% were 75 years of age and over. In monotherapy Study 20100007, of the 142 patients with wild-type RAS mCRC who received VECTIBIX, 39% were 65 years of age and over while 5% were 75 years of age and over.
EUEuropean Union· EMA
1 product
Uses
Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC): • in first-line in combination with FOLFOX or FOLFIRI. • in second-line in combination with FOLFIRI for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan).
• as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
How to take
Drug interactions
Known interactions involving Panitumumab. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB138320045 · revised August 22, 2025
- [2]Health Canada (DPD) · 02308487 · revised March 22, 2025
- [3]European Medicines Agency · EMEA/H/C/000741 · revised May 7, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.